160 related articles for article (PubMed ID: 20104215)
21. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Connell WR; Kamm MA; Dickson M; Balkwill AM; Ritchie JK; Lennard-Jones JE
Lancet; 1994 May; 343(8908):1249-52. PubMed ID: 7910274
[TBL] [Abstract][Full Text] [Related]
22. The rate of mucosal healing by azathioprine therapy and prediction by artificial systems.
Hardalaç F; Başaranoğlu M; Yüksel M; Kutbay U; Kaplan M; Özderin Özin Y; Kılıç ZM; Demirbağ AE; Coşkun O; Aksoy A; Gangarapu V; Örmeci N; Kayaçetin E
Turk J Gastroenterol; 2015 Jul; 26(4):315-21. PubMed ID: 26039001
[TBL] [Abstract][Full Text] [Related]
23. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.
Gupta G; Lautenbach E; Lewis JD
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1483-90. PubMed ID: 17162240
[TBL] [Abstract][Full Text] [Related]
24. Effect of Inflammatory Bowel Disease-Related Characteristics and Treatment Interventions on Cardiovascular Disease Incidence.
Thapa SD; Hadid H; Schairer J; Imam W; Jafri SM
Am J Med Sci; 2015 Sep; 350(3):175-80. PubMed ID: 26226548
[TBL] [Abstract][Full Text] [Related]
25. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
26. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.
Zhu Q; Cao Q
Chin Med J (Engl); 2012 Oct; 125(20):3665-70. PubMed ID: 23075721
[TBL] [Abstract][Full Text] [Related]
27. Distal adenomatous polyps are rare in patients with inflammatory bowel disease.
Dixon A; Wurm P; Hart A; Robinson R
Postgrad Med J; 2006 Jan; 82(963):76-8. PubMed ID: 16397087
[TBL] [Abstract][Full Text] [Related]
28. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.
Baars JE; Looman CW; Steyerberg EW; Beukers R; Tan AC; Weusten BL; Kuipers EJ; van der Woude CJ
Am J Gastroenterol; 2011 Feb; 106(2):319-28. PubMed ID: 21045815
[TBL] [Abstract][Full Text] [Related]
29. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
Singh H; Nugent Z; Demers AA; Bernstein CN
Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
[TBL] [Abstract][Full Text] [Related]
30. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.
Confavreux C; Saddier P; Grimaud J; Moreau T; Adeleine P; Aimard G
Neurology; 1996 Jun; 46(6):1607-12. PubMed ID: 8649558
[TBL] [Abstract][Full Text] [Related]
31. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
32. The association between corticosteroid use and development of fractures among IBD patients in a population-based database.
Bernstein CN; Blanchard JF; Metge C; Yogendran M
Am J Gastroenterol; 2003 Aug; 98(8):1797-801. PubMed ID: 12907335
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.
Masunaga Y; Ohno K; Ogawa R; Hashiguchi M; Echizen H; Ogata H
Ann Pharmacother; 2007 Jan; 41(1):21-8. PubMed ID: 17200426
[TBL] [Abstract][Full Text] [Related]
34. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
Shaye OA; Yadegari M; Abreu MT; Poordad F; Simon K; Martin P; Papadakis KA; Ippoliti A; Vasiliauskas E; Tran TT
Am J Gastroenterol; 2007 Nov; 102(11):2488-94. PubMed ID: 17764490
[TBL] [Abstract][Full Text] [Related]
35. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Jun; 20(6):942-8. PubMed ID: 23448676
[TBL] [Abstract][Full Text] [Related]
36. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD).
Shim L; Eslick GD; Simring AA; Murray H; Weltman MD
J Crohns Colitis; 2011 Jun; 5(3):234-8. PubMed ID: 21575887
[TBL] [Abstract][Full Text] [Related]
37. Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease: Results From a Tertiary Referral Center.
Eskazan T; Bozcan S; Atay K; Yildirim S; Demir N; Celik S; Tuncer M; Hatemi I; Celik AF; Erzin Y
Pancreas; 2021 Oct; 50(9):1274-1280. PubMed ID: 34860811
[TBL] [Abstract][Full Text] [Related]
38. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
Kwon JH; Farrell RJ
Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
[TBL] [Abstract][Full Text] [Related]
39. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Su C; Lichtenstein GR
Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
[TBL] [Abstract][Full Text] [Related]
40. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
Van Staa TP; Travis S; Leufkens HG; Logan RF
Gastroenterology; 2004 Jun; 126(7):1733-9. PubMed ID: 15188168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
